Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 in Healthy Adult Volunteers

To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.

Inclusion Criteria:

• Healthy adult volunteers aged ≥19 and <65 years at the time of the screening visit
• Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit

Exclusion Criteria:

• Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
• Other exclusions applied